Almac Sciences’ INSIGHT Platform Accelerates Genes-to-GMP Implementation
Modern generation of Active Pharmaceutical Ingredients (APIs) for human and animal health involve increasingly complex molecular structures, predominantly exemplified by chiral small molecules, ever-longer peptides, semi-natural oligonucleotides, and therapeutic antibodies. Biotechnology has always held a key role in accessing high molecular weight complexity.
Traditionally, complex structures like antibiotics, had to be produced by fermentation, whereas smaller chiral APIs were typically manufactured from a pool of chiral starting materials or classical resolution. This changed when modern asymmetric catalysis offered better productivity towards an ever-increasing range of accessible targets, resulting in APIs which were affordable and critically safe medicines for all.